The £330 Million Question Hanging Over Palantir's NHS Contract

A Review That Signals More Than Process

The UK government has confirmed it will review the contract under which Palantir Technologies provides software for NHS England's Federated Data Platform. The review carries weight: a contractual break clause arrives next February, and the platform sits at the centre of efforts to address England's post-pandemic elective care backlog. The decision to examine the arrangement reflects a broader unease about who controls critical health data infrastructure and whether the country should be building these capabilities domestically.

Palantir's journey into the NHS began during the pandemic, when it won a £1 contract to supply data tools under emergency conditions. That foothold expanded through £60 million in uncontested deals, then culminated in a £330 million award to deliver the Federated Data Platform under a software-as-a-service model. The platform was intended to help NHS England process the mountain of delayed procedures that accumulated during COVID-19 lockdowns. According to Palantir, the system has already contributed to 110,078 additional patients undergoing procedures in hospital theatres since implementation, and nearly seven percent more patients with suspected cancer referrals now receive results within 28 days compared to the twelve months before deployment.

Yet those outcomes have not quieted concern about the contract itself, the procurement process that led to it, or the long-term implications of relying on a US firm with deep ties to intelligence and immigration enforcement agencies. The company was founded with backing from In-Q-Tel, a venture capital arm connected to the CIA, and its client roster includes Immigration and Customs Enforcement alongside other security agencies that attract scrutiny. Since the Labour government took office, the political temperature around the deal has shifted.

Sovereignty, Standards, and the Absence of a Market

At a recent Digital and AI Sovereignty event organized by open source advocates OpenUK, Lord Paul Drayson, a member of the House of Lords Science and Technology Committee and founder of UK clinical AI firm Arcturis Data, welcomed the review. He argued that the original procurement did not meet the standard of transparent rules and equitable competition. For Drayson, the contract is emblematic of a broader values question: whether the UK has the political will to invest in domestic technology capacity when critical public infrastructure is at stake.

Mike Bracken, partner at consultancy Public Digital and a former Cabinet Office executive director for digital, framed the issue as a fifteen-year failure by NHS England to establish standardized health data taxonomies and classifications. Without those foundational standards, he argued, there can be no thriving supplier market. Instead, the absence of common frameworks has allowed a single entity to define the taxonomy and federated model, concentrating control in ways that are unhealthy for competition and innovation. Bracken emphasized that the problem is not Palantir specifically, but a pattern across the UK public sector in which officials profess belief in market orthodoxy yet preside over arrangements that resemble oligopolies or monopolies.

Laura Gilbert, Senior Director for AI at the Tony Blair Institute and former director of data science in the Prime Minister's Office, went further. She described the Federated Data Platform as precisely the type of use case that should not be outsourced, especially not to an offshore vendor. The UK possesses the skills to build its own NHS data systems, she said, and doing so would create spillover benefits for the wider technology and healthcare economy. Locking into a single vendor on such a critical platform introduces risk, and it means that the insights derived from patient data flow back to a company that can refine its products and sell them elsewhere, rather than feeding into continuous improvement of the UK health service itself. The Tony Blair Institute has received funding from Larry Ellison, co-founder of Oracle, which was part of a consortium that bid unsuccessfully for the FDP contract.

February's Fork in the Road

Health Secretary James Murray acknowledged the review during an interview, confirming that the contract is being examined ahead of the February break point. The next few months will determine whether Palantir retains its central role in NHS data infrastructure or whether the government decides to exercise the exit clause and chart a different course.

That decision will unfold against a backdrop of political uncertainty. If current speculation about leadership change proves accurate, the incoming administration may bring a different perspective on digital infrastructure and vendor relationships. Andy Burnham, currently mayor of Manchester and widely discussed as a potential successor to Prime Minister Keir Starmer, has overseen a different approach in his own region. The Greater Manchester Integrated Care Board rejected the Federated Data Platform in favor of a system built on Microsoft Azure, incorporating technology from data pipeline vendor Matillion, analytics and data lake company Snowflake, visualization firm Tableau, and the University of Manchester's eLab. A report from last year concluded that the Greater Manchester system exceeds the capabilities currently offered by the FDP.

That regional divergence is instructive. It demonstrates that alternative architectures are not only possible but already operational within the NHS system. The Greater Manchester model is multi-vendor, which in principle reduces lock-in risk and distributes both technical capability and commercial leverage across several suppliers. Whether that model is replicable at a national scale, and whether it can deliver the same or better clinical outcomes, remains an open question. But its existence challenges the narrative that there was no alternative to the Palantir contract.

Data as Asset, Data as Leverage

The debate over the FDP is ultimately about control. Health data is among the most valuable and sensitive assets a nation holds. The UK's National Health Service generates an extraordinary volume of clinical information, spanning decades and covering a population of tens of millions. Properly managed, that data can drive research, improve treatment protocols, identify disease patterns, and train artificial intelligence models with profound implications for global medicine. Improperly managed, it can be monetized by third parties, exposed to security breaches, or become a dependency that constrains future policy choices.

At DailyTechWire, we have tracked similar debates across Asia, where governments in Seoul, Singapore, and New Delhi have each grappled with questions of data sovereignty in healthcare, finance, and telecommunications. The common thread is a growing recognition that critical infrastructure built on proprietary platforms controlled by foreign vendors can become a strategic vulnerability. The calculus is not purely technical; it involves trade policy, national security, industrial strategy, and the long-term competitiveness of domestic technology sectors.

In the UK context, the Palantir contract crystallizes these tensions. The company's technology may deliver measurable improvements in patient throughput and diagnostic speed. But those gains must be weighed against the opportunity cost of not building equivalent capability domestically, the risk of vendor dependency, and the question of where the learning and value accumulation from NHS data ultimately reside.

What Comes Next

If the review leads to termination in February, NHS England will need a transition plan. Migrating a platform of this scale is not trivial. It requires data portability, staff retraining, continuity of clinical operations, and a clear alternative architecture. The Greater Manchester example offers a blueprint, but scaling it nationally would demand coordination across multiple integrated care boards, each with its own IT legacy and procurement preferences. The alternative is to negotiate new terms with Palantir that address some of the sovereignty and lock-in concerns, possibly through data residency requirements, open standards commitments, or technology transfer provisions.

A third path, less likely but worth considering, would be a hybrid model in which Palantir's software continues to operate in the short term while the UK invests in parallel development of open-source or domestically controlled alternatives. This would hedge risk and buy time, but it would also require sustained political commitment and funding at a moment when public finances are constrained.

The outcome will send a signal well beyond healthcare. If the UK chooses to exit the Palantir contract and invest in domestic capacity, it will mark a shift in how the government approaches digital infrastructure procurement. If it renews or extends the arrangement, it will confirm a model in which efficiency and speed take precedence over sovereignty and market development. Both choices carry consequences, and both reflect deeper assumptions about what kind of digital economy the UK wants to build in the years ahead.